Eton Pharmaceuticals, Inc. Long-Term Debt, Maturity, Year Five
Eton Pharmaceuticals, Inc. (ETON) had Long-Term Debt, Maturity, Year Five of $3.81 million as of 2020-03-31, per its 10-Q filed 2020-05-14.
Discontinued › Notes › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2020-05-14
- 2020-03-31: Long-Term Debt, Maturity, Year Five $3.81M.
- 2019-12-31: Long-Term Debt, Maturity, Year Five $3.81M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2020-03-31 | $3.81M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $3.81M 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |